A Study to Compare Genetic Variations of IGF-I and IGF-II

Completed

• Conditions: Dementia

• Registration Number: NCT01329523
• Lead Sponsor: Avera McKennan Hospital & University Health Center

Brief Summary

The purpose of this study is to determine if insulin-like growth factors (IGF) play a role in the development of dementia, specifically Alzheimer's disease (AD). The study will compare results from genetic testing between patients with AD and two other groups: younger biological family members of the AD patients and individuals without AD matched by age to the AD patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Status Verified: 2011-01
• Study First Submitted: 2011-01-10
• Study First Submitted QC: 2011-04-04
• Study First Posted: 2011-04-06
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Last Update Submitted: 2011-10-04
• Last Update Posted: 2011-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Men and women between the ages of 50 and 81 years old who have a diagnosis of dementia
• Men and women who are at least 18 years old and are biologically related to the study subject with dementia
• Control subjects must not have a diagnosis of dementia and must be matched in age to the study subjects with dementia

Exclusion Criteria

• Biological family members of the dementia patient who are either younger than 17 years of age or older than the patient with dementia
• Biological family members with a diagnosis of dementia
• Age-matched control subjects with a diagnosis of dementia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genetic polymorphisms of insulin-like growth factors	Single clinic visit (day 1)	This study consists of a single clinic visit. After subject has completed the informed consent process and meets eligibility criteria, a blood sample and a saliva sample will be collected. Genetic results from this one-time specimen collection will be evaluated and compared with results from participants in the other two study groups. Outcomes will be measured comparatively.

Secondary Outcome Measures

Name	Time	Method
Genetic testing of Apolipoprotein (APO) E4	Single clinic visit (day 1)	This study consists of a single clinic visit. After subject has completed the informed consent process and meets eligibility criteria, a blood sample and a saliva sample will be collected. Genetic results from this one-time specimen collection will be evaluated and compared with results from participants in the other two study groups. Outcomes will be measured comparatively.

Trial Locations

Locations (1)

Avera Research Institute; 🇺🇸 Sioux Falls, South Dakota, United States